Trial Profile
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary) ; Dapagliflozin (Primary) ; EDP-1815 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms TACTIC-E
- 26 Jul 2023 Status changed from recruiting to completed.
- 04 Jan 2022 According to an Evelo Biosciences media release, interim safety and futility analysis of 375 patients (125 patients from each arm) is expected in 1H 2022.
- 28 Oct 2021 According to an Evelo Biosciences media release, the company is progressing recruiting with the addition of clinical study sites in the UK, Brazil, India, and Mexico.